Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 1, 2006, Pages 44-52

  Jarjour, Nizar N ^a   Wilson, Susan J ^b   Koenig, Steven M ^c   Laviolette, Michel ^d   Moore, Wendy C ^e   Davis, W Bruce ^f   Doherty, Dennis E ^g   Hamid, Qutayba ^h   Israel, Elliott ⁱ   Kavuru, Mani S ^j   Ramsdell, Joe W ^k   Tashkin, Donald P ^l   Reilly, Donna S ^m   Yancey, Steven W ^m   Edwards, Lisa D ^m   Stauffer, John L ^m   Dorinsky, Paul M ^m   Djukanovic, Ratko ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m GLAXOSMITHKLINE   (United States)

more..

Author keywords

biopsy; bronchoalveolar lavage; eosinophils; Fluticasone propionate; salmeterol

Indexed keywords

CD3 ANTIGEN; FLUTICASONE PROPIONATE PLUS SALMETEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8;

ADULT; ALLERGIC ASTHMA; ARTICLE; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; EOSINOPHIL; FEMALE; HEART PALPITATION; HUMAN; HUMAN TISSUE; INHALER; LOW DRUG DOSE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MAST CELL; MONITORING; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SCREENING; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 33745356774     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.03.043     Document Type: Article

References (34)

1. Barnes P.J., Pedersen S., and Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157 suppl (1998) 1S-53S
2. Umland S.P., Schleimer R.P., and Johnson S.L. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 15 (2002) 35-50
3. Wallin A., Sue-Chu M., Bjermer L., Ward J., Sandstrom T., Lindberg A., et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 112 (2003) 72-78
4. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 90 (1992) 32-42
5. Ward C., Pais M., Bish R., Reid D., Feltis B., Johns D., and Walters E.H. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57 (2002) 309-316
6. Wong C.A., Walsh L.J., Smith C.J.P., Wisniewski A.F., Lewis S.A., Hubbard R., et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355 (2000) 1399-1403
7. Cumming R.G., Mitchell P., and Leeder S.R. Use of inhaled corticosteroid and the risk of cataracts. N Engl J Med 337 (1997) 8-14
8. McIvor R.A., Pizzichini E., Turner M.O., Hussack P., Hargreave F.E., and Sears M.R. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158 (1998) 924-930
9. Lemanske R.F., Sorkness C.A., Mauger E.A., Lazarus S.C., Boushey H.A., Fahy J.V., et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA 285 (2001) 2594-2603
10. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285 (2001) 2583-2593
11. Busse W., Koenig S.M., Oppenheimer J., Sahn S.A., Yancey S.W., Reilly D., et al. Steroid-sparing effects of FP 100mcg and salmeterol 50mcg BID administered in a single product in patients previously controlled with FP 250mcg BID. J Allergy Clin Immunol 111 (2003) 57-65
12. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136 (1987) 225-244
13. Britten K.M., Howarth P.H., and Roche W.R. Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem 68 (1993) 271-280
14. Sullivan P., Stephens D., Ansari T., Costello J., and Jeffery P. Variation in measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur Respir J 12 (1998) 811-815
15. Kraft M., Martin R.J., Lazarus S.C., Fahy J.V., Boushey H.A., Lemanske R.F., et al. Airway tissue mast cells in persistent asthma. Predicator of treatment failure when patients discontinue inhaled corticosteroids. Chest 124 (2003) 42-50
16. Chetta A., Foresi A., Del Donno M., Bertorelli G., Pesci A., and Oliveri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 111 (1997) 852-857
17. Efron B., and Tibshirani R.J. An introduction to the bootstrap (1993), Chapman and Hall, London
18. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
19. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 (2000) 1368-1373
20. Anonymous. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 141 suppl (1990) S169-S202
21. Hunninghake G.W., and Crystal R.G. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 128 (1983) 833-836
22. Thompson A.B., Daughton D., Robbins R.A., Ghafouri M.A., Oehlerking M., and Rennard S.I. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 140 (1998) 1527-1537
23. Anonymous. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 22 (2003) 470-477
24. Wenzel S.E., Szefler S.J., Leung D.Y., Sloan S.I., Rex M.D., and Martin R.J. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 156 (1997) 737-743
25. Kips J.C., O'Connor B.J., Inman M.D., Svensson K., Pauwels R.A., and O'Byrne P.M. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 161 (2000) 996-1001
26. Bentley A.M., Menz G., Storz C., Robinson D.S., Bradley B., Jeffery P.K., et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis 146 (1992) 500-506
27. Louis R., Lau L.C., Bron A.O., Roldaan A.C., Radermecker M., and Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161 (2000) 9-16
28. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
29. Green R.H., Brightling C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002) 1715-1721
30. Nelson H.S., Chapman K.R., Pyke S.D., Johnson M., and Pritchard J.N. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 112 (2003) 29-36
31. 2-agonists and corticosteroids. Curr Allergy Clin Immunol 15 (2002) 16-22
32. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274 (1999) 1005-1010
33. 2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 155 (1997) 704-710
34. 2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360 (2002) 1293-1299